G01N 2333/7051
T-cell receptor -cd3 complex
Official title: T-cell receptor (TcR)-CD3 complex
G01N2333/7051 (T-cell receptor -cd3 complex) appears on 210 US grants and 435 published applications in this corpus.
Search patents in G01N- Granted patents
- 210
- Published applications
- 435
- Assignees
- 222
- Inventors
- 830
- Latest grant
- 28 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 1 |
| 2003 | 1 | 2 |
| 2004 | 1 | 2 |
| 2005 | 0 | 1 |
| 2006 | 0 | 1 |
| 2007 | 0 | 1 |
| 2008 | 1 | 2 |
| 2009 | 1 | 9 |
| 2010 | 1 | 3 |
| 2011 | 0 | 5 |
| 2012 | 0 | 16 |
| 2013 | 2 | 4 |
| 2014 | 4 | 11 |
| 2015 | 4 | 24 |
| 2016 | 9 | 40 |
| 2017 | 12 | 20 |
| 2018 | 35 | 41 |
| 2019 | 26 | 30 |
| 2020 | 15 | 34 |
| 2021 | 24 | 32 |
| 2022 | 17 | 26 |
| 2023 | 17 | 37 |
| 2024 | 16 | 30 |
| 2025 | 16 | 39 |
| 2026 | 3 | 24 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Screening and antitumor use of KRAS mutation specific T cell receptor28 Jul 2026US 12,692,298 B2Institute of Microbiology, Chinese Academy of Sciences
- Inhibitory T cell receptor peptides and discovery methods21 Apr 2026US 12,606,816 B2Janux Therapeutics, Inc.
- Detection of early-stage lung cancer in sputum using automated flow cytometry and machine learning3 Feb 2026US 12,542,215 B2bioAffinity Technologies, Inc.
- Nanoscale reaction chambers and methods of using the same23 Dec 2025US 12,503,723 B1Partillion Bioscience Corporation
- Method of monitoring treatment16 Dec 2025US 12,497,663 B2LDN Pharma Limited
- Compositions and methods for determining the effects of t cell engager8 Oct 2026US 2026/0309708 A1Arbele Limited
- Mutated t cell receptor beta chain3 Sep 2026US 2026/0256840 A1The Regents of the University of California
- Assessing and treating mesothelioma3 Sep 2026US 2026/0259215 A1Mayo Foundation for Medical Education and Research
- Methods for characterization of antigen-binding molecules from biological samples27 Aug 2026US 2026/0250663 A110x Genomics, Inc.
- Hla-a3-restricted t cell receptors against braf with v600e mutation20 Aug 2026US 2026/0242513 A1The United States of America, as represented by the Secretary, Department of Health and Human Servic
Most cited
By later US patents
- Tolerogenic synthetic nanocarriers for inducing regulatory B cells129US 8,652,487 B2Selecta Biosciences, Inc. · 2014
- Cell free T cell antigen receptor beta chain and its clinical utilities66US 5,436,319 AT Cell Sciences, Inc. · 1995
- High affinity TCR proteins and methods55US 7,569,357 B2The Board of Trustees of the University of Illinois · 2009
- Peptides and combination of peptides for use in immunotherapy against various tumors45US 9,802,997 B2Immatics Biotechnologies GmbH · 2017
- Tolerogenic synthetic nanocarriers42US 9,265,815 B2Selecta Biosciences, Inc. · 2016